Mukul R Jain, PhD

Senior Vice President
Zydus Research Centre
Pharmacology and Toxicology

Biographical Sketch:
Dr. Mukul Jain is a Senior Vice President at Zydus Research Centre, the New Drug Discovery Research wing of Zydus Cadila. Dr. Jain has led the team that successfully developed Saroglitazar, the first indigenously discovered & developed new drug from an Indian Pharmaceutical Company and world’s first approved ‘Glitazar’ class drug, which is being marketed under the brand name LipaglynTM. Besides Saroglitazar, his group has also developed 11 other NCEs (New Chemical Entities) that have entered human clinical trials. He has also contributed to development of 10 recombinant biosimilar products and 8 vaccines; many of these generic products have come to market as well. Dr. Jain has a background in Pharmaceutical Sciences. He obtained his B.Pharm., M.Pharm (Pharmacology) and PhD in Medicine from Nagpur University. He also holds a diploma in Business Management from Nagpur University and a Certificate in Executive Management from IIM, Ahmedabad. After completing his PhD, he worked at Wockhardt and Ranbaxy Research Centers before moving to University of Florida at Gainesville, where he worked as Post-doc Associate for three years. He then returned to India & joined NIPER, the National Institute of Pharmaceutical Education & Research at Mohali as Assistant Professor. In the year 2000 he moved to Ahmedabad and joined Zydus Research Centre, where he developed a state of the art preclinical research facilities and obtained several quality-related accreditations for the facility from various national & international agencies. Dr. Jain has contributed to more than 38 patents as co-inventor and has more than 195 research publications to his credit, which include more than 95 full length research papers in peer-reviewed International journals. He has guided the research work of 8 PhD students and several Masters Students. Dr. Jain is a member of several National & International Scientific Associations.
Papers:
LB-PP02-4 ZYDPLA1, a Novel Long-Acting DPP-4 Inhibitor